NorthWest Biotherapeutics Inc (NWBO)

[j e d]

Focusing solely on methylated patients, NWBO looks solid:

Looking just at the MGMT methylated patients, and varying placebo mOS and varying the DCVax:Placebo ratio (as we don't know it within just the methylated group, although since the trial is randomized it should be close to the overall ratio of 2.34:1), here is what I found to be the mOS of MGMT methylated patients who were administered DCVax:



If management chose to cater to specifically MGMT methylated ndGBM patients, DCVax would surely be statistically significant with these improvements, no? IMHO.